Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493778 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT01493778 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 60 participants.
The verdict
NCT01493778, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe and North America. The purpose of the trial is to evaluate the safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with haemophilia A.
Interventions
- DRUG turoctocog alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-09-17 |
| Est. Completion | 2018-12-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01493778
The ClinicalTrials.gov registry entry for NCT01493778 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which turoctocog alfa is the first listed.
NCT01493778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01493778 about?
NCT01493778 is a clinical study titled "Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A". This trial is conducted in Asia, Europe and North America. The purpose of the trial is to evaluate the safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with haemophilia A.
What is the current status of trial NCT01493778?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2012-09-17. Estimated completion is 2018-12-05.
What interventions are being tested in trial NCT01493778?
The interventions under investigation include: turoctocog alfa (DRUG).
Who is sponsoring clinical trial NCT01493778?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.